Literature DB >> 10813711

Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1.

K D Fralix1, M M Ahmed, C Mattingly, C Swiderski, P C McGrath, K Venkatasubbarao, N Kamada, M Mohiuddin, W E Strodel, J W Freeman.   

Abstract

BACKGROUND: A highly tumorigenic cell line designated as UK Pan-1 was established in a surgically removed human pancreatic adenocarcinoma and characterized as having many of the genotypic and phenotypic alterations commonly found in pancreatic tumors.
METHODS: The cell line was characterized by its morphology, growth rate in monolayer culture and soft agar, tumorigenicity in nude mice, and chromosomal analysis. Furthermore, the status of p53, Ki-ras mutation and transforming growth factor (TGF)-/receptor expression were determined. The characteristics of UK Pan-1 were compared with those of other commonly used pancreatic carcinoma cell lines.
RESULTS: Quiescent UK Pan-1 cells could be stimulated to proliferate in growth factor free nutrient media, indicating a growth factor independent phenotype. UK Pan- 1 cells grew in soft agar and rapidly formed tumors in nude mice. This cell line possesses a mutation at codon 12 of the c-Ki-ras-2 gene that is commonly found in pancreatic carcinoma. Fluorescence in situ hybridization showed that two alleles of p53 tumor suppressor gene were present in UK Pan-1. However, sequencing analysis revealed a mutation in one allele at exon 8, codon 273 (G to A; Arg to His). Additional growth assays indicated that the cell line was insensitive to negative growth regulation induced by exogenous TGF-beta. Molecular analysis of the TGF-beta signaling pathway showed that UK Pan-1 did not express appreciable levels of the TGF-beta receptor type I, II, or III mRNAs, but did express DPC4 mRNA. Karyotype analysis revealed an 18q21 deletion indicating a possible loss of heterozygosity for DPC4, as well as other chromosomal deletions and rearrangements.
CONCLUSIONS: This study indicates that UK Pan-1 is a highly tumorigenic cell line possessing a molecularly complex pattern of mutations that may be used as a model to further the understanding of the mechanisms responsible for the development of pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813711     DOI: 10.1002/(sici)1097-0142(20000501)88:9<2010::aid-cncr5>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.

Authors:  Shujie Zhao; Chen Chen; Katherine Chang; Anand Karnad; Jaishree Jagirdar; Addanki P Kumar; James W Freeman
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

2.  Inhibition of transforming growth factor-beta signaling in normal lung epithelial cells confers resistance to ionizing radiation.

Authors:  Anna Reeves; Marianna Zagurovskaya; Seema Gupta; Mohammed M Shareef; Mohammed Mohiuddin; Mansoor M Ahmed
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

3.  Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.

Authors:  Shujie Zhao; Sudhakar Ammanamanchi; Michael Brattain; Lin Cao; Amalraj Thangasamy; Jing Wang; James W Freeman
Journal:  J Biol Chem       Date:  2008-02-29       Impact factor: 5.157

4.  Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.

Authors:  Kolaparthi Venkatasubbarao; Lindsay Peterson; Shujie Zhao; Ping Hill; Lin Cao; Qing Zhou; Steffan T Nawrocki; James W Freeman
Journal:  Mol Cancer       Date:  2013-09-11       Impact factor: 27.401

5.  Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.

Authors:  S Zhao; L Cao; J W Freeman
Journal:  Oncogenesis       Date:  2013-10-07       Impact factor: 7.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.